{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-003048","form_type":"8-K","ticker":"RARE","cik":"0001515673","company_name":"Ultragenyx Pharmaceutical Inc.","filed_at":"2023-02-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.347084+00:00","generated_at":"2026-06-19T09:17:08.204698+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Ultragenyx reports FY2022 net loss $707M, revenue $363M; guides 2023 rev $425-450M","bullets":["FY2022 total revenue $363.3M (+3% YoY) from $351.4M in 2021.","Net loss $707.4M ($10.12/sh) vs $454.0M ($6.70) in 2021, driven by higher R&D and acquired IP.","Crysvita revenue $279.4M, Dojolvi $55.6M, Mepsevii $20.6M; cash $896.7M at year-end.","2023 guidance: total rev $425-450M; Crysvita $325-340M; Dojolvi $65-75M; net cash use <$400M.","Q4 net loss $151.8M ($2.16/sh) vs $122.5M ($1.79) in Q4 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-003048","json":"https://secwatch.observer/filing/0000950170-23-003048.json","markdown":"https://secwatch.observer/filing/0000950170-23-003048.md","text":"https://secwatch.observer/filing/0000950170-23-003048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1515673/000095017023003048/0000950170-23-003048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1515673/000095017023003048/rare-20230216.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T09:17:08.204698+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"26e3734ddc543d868a9b604d46e1ee1189f0793a","claim":"Ultragenyx Pharmaceutical Inc. reported Full year 2023 results: revenue Crysvita $325 million to $340 million; Dojolvi $65 million to $75 million. Guidance reaffirmed.","evidence_excerpt":"Total revenue in the range of $425 million to $450 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017023003048/0000950170-23-003048-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full year 2023"},{"label":"Revenue","value":"Crysvita $325 million to $340 million; Dojolvi $65 million to $75 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"26e3734ddc543d868a9b604d46e1ee1189f0793a","claim":"Ultragenyx Pharmaceutical Inc. reported Full year 2023 results: revenue Crysvita $325 million to $340 million; Dojolvi $65 million to $75 million. Guidance reaffirmed.","evidence_excerpt":"Crysvita revenue in the range of $325 million to $340 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017023003048/0000950170-23-003048-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full year 2023"},{"label":"Revenue","value":"Crysvita $325 million to $340 million; Dojolvi $65 million to $75 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"d81a84c3108d7f50d25b0922a9be1d30b1ba9043","claim":"Ultragenyx Pharmaceutical Inc. reported three months ended December 31, 2022 and year ended December 31, 2022 results: revenue $103.3 million for Q4 2022; $363.3 million for FY 2022, net income Net loss of $151.8 million for Q4 2022; Net loss of $707.4 million for FY 2022, EPS $(2.16) per share for Q4 2022; $(10.12) per share for FY 2022. Guidance reaffirmed.","evidence_excerpt":"Ultragenyx Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017023003048/0000950170-23-003048-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended December 31, 2022 and year ended December 31, 2022"},{"label":"Revenue","value":"$103.3 million for Q4 2022; $363.3 million for FY 2022"},{"label":"Net income","value":"Net loss of $151.8 million for Q4 2022; Net loss of $707.4 million for FY 2022"},{"label":"EPS","value":"$(2.16) per share for Q4 2022; $(10.12) per share for FY 2022"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}